CDK9 is a promising therapeutic target for the individualized therapy of pancreatic cancer, deserving of more preclinical and clinical research due to its ability to selectively target cancer cells and work in concert with conventional treatments [161]. The gene discussed is CDK9; the disease is familial pancreatic carcinoma.